background: Follistatin levels have recently been considered as a marker for inflammation. Our objective was to evaluate the level of circulating follistatin and high-sensitivity C-reactive protein (hsCRP) in women with polycystic ovary syndrome (PCOS) after oral contraceptive (OC) treatment.
Introduction
Young women with polycystic ovary syndrome (PCOS) are reported to have an increase in cardiovascular risk factors, such as obesity, insulin resistance (IR), impaired glucose tolerance, endothelial dysfunction, elevated blood pressure and metabolic syndrome (Tarkun et al., 2004; Chen et al., 2006 Chen et al., , 2007 . Oral contraceptives (OCs), such as the ethinyl estradiol-cyproterone acetate (EE-CA, , are one of the most common treatments for young women with PCOS. Not only are OCs a well established, efficient method to prevent unwanted pregnancies, but they can also be used to induce cyclic uterine withdrawal bleeding to reduce the risk of endometrial cancer (The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and † The partial content of this work was orally presented at the Annual Meeting of the American Society for Reproductive Medicine on October 20, 2009. Human Development, 1987) and to improve phenotypic hyperandrogenism in women with PCOS. However, the association between the risk of future cardiovascular disease and the use of OCs is controversial (Baird and Glasier, 1993) .
The role of inflammation in the pathogenesis of cardiovascular disease is well established. C-reactive protein is an acute-phase reactant synthesized in the liver in response to inflammatory cytokines and recently has been considered as a strong predicator of cardiovascular disease risk (Pearson et al., 2003) . Recent studies have reported that hormone treatment is associated with elevated high-sensitivity Creactive protein (hsCRP) and IR levels in normal, healthy, cycling young women (Viikari et al., 2007; Cauci et al., 2008) , middle aged women (Ridker et al., 1999) and also in women with PCOS (MorinPapunen et al., 2003) . However, the sample size in the study by MorinPapunen et al. was limited (only 8-10 subjects in each group), thus cannot yield convincing results of how obesity and OC treatment affect hsCRP levels in women with PCOS.
Follistatin, a carrier protein of the transforming growth factor (TGF)-b superfamily, is expressed in various tissues (Sakamoto et al., 1996) and has recently been reported to have a role in the modulation of the inflammatory reaction (Dohi et al., 2005) and also in the occurrence of atherosclerosis (Chang et al., 2007) . Follistatin secretion may respond to inflammatory stimuli. For instance, the concentration of follistatin in humans may increase in cerebrospinal fluid during meningitis (Michel et al., 2000) and increase in peripheral circulation during septicemia (Michel et al., 2003) . Therefore, elevated follistatin concentrations may represent an inflammatory state. Circulating follistatin levels have been shown to be higher in women with PCOS than those without PCOS (Eldar-Geva et al., 2001; Norman et al., 2001; Chen et al., 2009) . This high extragonadal circulating follistatin level is postulated to be related to the high prevalence of chronic low-grade inflammation, represented by elevated hsCRP levels, in women with PCOS (Chen et al., 2009) . However, whether changes in follistatin levels follow changes in hsCRP levels, especially after treatment with OCs, is not known. Therefore, our aim in this prospective study was to evaluate the follistatin and hsCRP levels after OC treatment in women with PCOS, with consideration of the confounding effect of obesity.
Materials and Methods

Subjects
From our reproductive endocrinology clinic, 56 women, with PCOS and a chief complaint of irregular menstrual cycles and/or clinical hyperandrogenism, were enrolled into the study protocol. The study was approved by the Institutional Review Board of the National Taiwan University Hospital. Informed consent was obtained from all the subjects and/or their parents. The detailed inclusion and exclusion criteria for enrollment of the subjects have been described previously (Chen et al., 2007 (Chen et al., , 2008 . Briefly, the diagnosis of PCOS was based on the Rotterdam criteria, in which at least two of the following three criteria were met: oligomenorrhea or amenorrhea, biochemical hyperandrogenemia and polycystic ovaries. Exclusion criteria included the presence of other endocrine, organic and systemic abnormalities, such as hyperprolactinemia, thyroid dysfunction, Cushing's syndrome, congenital adrenal hyperplasia, adrenal or ovarian tumors, current pregnancy or previous pregnancy within 1 year of enrollment, autoimmune disease, malignancy, central nervous disease, a history of recent infection, dysmenorrhea and a smoking habit. Subjects who were users of medications, such as current or previous use of OCs within 6 months of enrollment or medications known to affect the hypothalamic -pituitary -ovarian axis, such as antiandrogens, ovulation induction agents, antidiabetic medications, anti-obesity medications or glucocorticoids, were also excluded from study. Phenotypic hirsutism was defined as a Ferriman -Gallwey score .8. According to guidelines reported for the adult Asian population (Shiwaku et al., 2004) , obesity was defined as body mass index (BMI) 25 kg/m 2 and non-obesity was defined as BMI , 25 kg/m 2 .
Study protocol and serum sampling
After a baseline evaluation, all selected subjects were treated for 3 months with EE-CA (ethinyl estradiol 35 mg, cyproterone acetate 2 mg; Diane-35, Bayer Shering Pharma AG, Germany) for 21days/month followed by a 7-day pill-free period. All assessments and blood sampling were performed at baseline and after 3 months of treatment. At baseline, overnight fasting blood samples were collected from PCOS subjects with amenorrhea exceeding 3 months without hormone-induced withdrawal bleeding and between Days 3 and 7 of the menstrual cycle from those women with PCOS who ovulated spontaneously. After 3 months of treatment, fasting blood samples were obtained on Days 2-5 of withdrawal bleeding during the pill-free period. Blood samples were collected before anthropometric measurements, and pelvic ultrasounds were performed. If a dominant follicle (.10 mm) was identified by pelvic ultrasound, the subject's blood sample was not collected. If the serum estradiol level was .150 pg/mL or the serum progesterone was .2 ng/mL, the collected blood samples were discarded and the subject's blood sample was collected again following menstruation. Blood was processed within 30 min of collection. Blood glucose and insulin samples were stored at 48C and analyzed on the day of sampling. Serum and plasma were aliquoted and frozen at 2708C until the assays.
Assay methods
The concentration of plasma glucose, serum levels of insulin, lipid profiles [i.e. total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C)], and the hormone profiles [i.e. follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone and sex hormone-binding globulin (SHBG)] were measured as described previously (Chen et al., 2006) . Serum total testosterone and dehydroepiandrosterone sulfate (DHEA-S) were measured by radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX, USA). The homeostasis model assessment (HOMA) and free androgen index (FAI) were applied to estimate the degree of IR and bioavailable testosterone, respectively. Homeostasis model assessment of insulin resistance (HOMA-IR) and FAI were calculated as described previously (Chen et al., 2007) . The plasma hsCRP concentration was assayed using an automated immunoturbidimetric method (TBA-200FR, Toshiba, Tokyo, Japan). Plasma follistatin levels were determined by an enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA). Samples were analyzed in duplicate and in random order to reduce inter-assay variation. The mean of the duplicated data was used for analysis. The intra-assay and inter-assay coefficients of variation of the aforementioned assays were ,10%.
Statistical analysis
Numeric variables are presented as the mean + standard deviation (SD) or median with interquartile range. The Shapiro-Wilk W test was used to identify whether the variables were normally distributed. Parametric comparisons with paired t test were used to compare the differences between baseline and after OC treatment. Wilcoxon's signed rank test was used to compare the differences of variables, between baseline and after treatment, with significant deviation from a normal distribution. Spearman rank correlations were used to determine the relationships between the differences in variables after intervention and also the correlations between hsCRP and follistatin with or without adjustment for BMI at baseline and after treatment. Student's t test was used to compare the difference in follistatin between obese and non-obese women with PCOS. A P-value of ,0.05 was considered statistically significant. All statistical analyses were performed using the PC version of the Statistical Analysis System (SAS, version 9.1; SAS Institute, Inc., Cary, NC, USA).
Results
A total of 56 women with PCOS were enrolled in this study. The mean age was 24.80 + 4.77 years and the mean BMI was 24.33 + 5.79 kg/m 2 . The biochemical features of the subjects at baseline and after therapy are presented in Table I . As expected, FSH, LH, E2, testosterone, FAI and DHEAS decreased (P ¼ 0.0156, P , 0.0001, P ¼ 0.048, P , 0.0001, P , 0.0001 and P , 0.0001, respectively) and SHBG rose (P , 0.0001) significantly after treatment with OCs for 3 months. No significant differences were found in BMI, fasting glucose, insulin and HOMA-IR; however, total cholesterol, triglycerides, HDL-C and LDL-C were found to increase significantly after therapy (P , 0.0001, P , 0.0001, P , 0.0001 and P ¼ 0.0013, respectively). In addition, hsCRP and follistatin levels were also significantly elevated after treatment (P ¼ 0.002 and P,0.0001, respectively).
To determine the effect of obesity on hormone levels and metabolic profiles after OC treatment, we divided the women with PCOS into two groups using a BMI cutoff of 25 kg/m 2 as shown in Table II . For obese women with PCOS, the serum levels of LH, testosterone and FAI still decreased significantly, and the levels of follistatin, triglycerides, HDL-C and SHBG still increased significantly after 3 months of OC therapy. However, the suppression of DHEAS level and the elevation of hsCRP, LDL-C and total cholesterol were not significant in obese women with PCOS after OC treatment (Table II) . On the contrary, in non-obese women with PCOS, FSH, LH, testosterone, FAI and DHEAS were all significantly suppressed after therapy. Although the BMI and fasting glucose level did not change, fasting insulin, HOMA-IR, total cholesterol, HDL-C, LDL-C, triglycerides and SHBG significantly increased after treatment. In addition, hsCRP and follistatin were also significantly elevated in nonobese women with PCOS after OC treatment. Collectively, the aggravation of IR and low-grade inflammation after OC treatment, manifested as elevated fasting insulin, HOMA-IR and hsCRP, were more evident in non-obese than obese women with PCOS (Table II) . However, although follistatin levels were significantly higher in obese than non-obese women with PCOS (P ¼ 0.040), its concentration was significantly elevated after OC treatment both in obese and non-obese women (Table II) . Circulating hsCRP and follistatin concentrations were significantly correlated at baseline (r ¼ 0. Wilcoxon's signed rank test were used in comparing the difference between baseline and after 3 months of oral contraceptive treatment.
Elevated follistatin after OC in women with PCOS significance for correlation after OC treatment for 3 months (r ¼ 0.24233, P ¼ 0.0719). The positive correlation between hsCRP and follistatin persisted after adjustment for BMI. The correlations of the changes of circulating hsCRP and follistatin levels after OC treatment for 3 months with the concurrent changes of body composition, metabolic profiles and hormone levels are presented in Table III . The different levels of hsCRP between baseline and after OC treatment were significantly and positively correlated with the concurrent changes of follistatin level (P ¼ 0.0033). In addition, the different levels of hsCRP and follistatin between baseline and after OC treatment for 3 months were also significantly correlated with the concurrent changes in triglyceride levels (P ¼ 0.0109 and P ¼ 0.0013, respectively).
Discussion
In the present study, we observed that the surrogate markers for lowgrade inflammation, hsCRP and follistatin were significantly increased after treatment with OCs for 3 months. The concurrent increase in the levels of hsCRP and follistatin after OC therapy in this study confirms our previous observation (Chen et al., 2009 ) that the characteristic elevated follistatin levels in women with PCOS is related to their high hsCRP levels. There is significant evidence to suggest that obesity and IR may activate inflammatory signal pathways and lead to exaggerated low-grade inflammation (Weisberg et al., 2003; Xu et al., 2003; Shoelson et al., 2007) . Chronic low-grade inflammation is thought to have an important role in the development and progression of arthrosclerosis (Pai et al., 2004) . Women with PCOS are well known to have a high prevalence of IR, obesity and low-grade inflammation as evidenced by elevated inflammatory markers such as CRP (Kelly et al., 2001; Boulman et al., 2004) , inflammatory cytokines (IL-6, IL-18 and TNF-a) (Gonzalez et al., 1999; Escobar-Morreale et al., 2004; Mohlig et al., 2004) and leukocyte count (Orio et al., 2005) . Among them, CRP is known to be associated with IR independent of obesity, and widely accepted as a strong predictor of cardiovascular disease risk (Pearson et al., 2003) . OCs are a common treatment for controlling irregular menstruation, amenorrhea and phenotypic hyperandrogenism in women with PCOS. However, there is only limited evidence suggesting that OC use in women with PCOS may further increase inflammation and their risk for cardiovascular disease (Morin-Papunen et al., 2003) .
OCs have been reported to have adverse impact on the cardiovascular system, mostly due to the pro-inflammatory and pro-thrombotic effects (Tanis et al., 2001) . Although the hsCRP levels have been noted to be significantly higher in healthy, young, normal weight OC users than in non-OC users (Cauci et al., 2008) , the levels of other acute-phase inflammatory markers such as IL-6 and TNF-a have been reported to be unaffected by OC use (van Rooijen et al., 2006 Table I for abbreviations; NS, non-significance at P 0.1. a Paired t test. b Wilcoxon signed rank test was used in comparing the difference between the baseline and after oral contraceptive treatment for 3 months.
post-menopausal women has been reported to produce higher levels of CRP than transdermal therapy, indicating that the route of hormone administration may also be a major determinant of CRP levels (Vehkavaara et al., 2001) . Therefore, the increased CRP level seen after the administration of OCs might be due to a direct effect from increased hepatocyte synthesis rather than from the classical IL-6-dependent inflammation process. Taken collectively, it is still uncertain if the elevated hsCRP levels seen after OC therapy in women with PCOS as shown in the present study represent an aggravated inflammatory response. The secretion of follistatin in response to stimuli is parallel to, but delayed when compared with the release of other pro-inflammatory cytokines such as IL-6 and TNF-a (Jones et al., 2004 (Jones et al., , 2007 . Follistatin was recently shown to have an anti-inflammatory effect in murine models of colitis or endotoxemia (Dohi et al., 2005; Jones et al., 2007) , and it can be stimulated in aortic and vascular endothelial cells by bacterial compounds (Michel et al., 1996; Wilson et al., 2006) . Additionally, follistatin can also attenuate oscillatory shear stress induced vascular inflammation and further reduce the development of arthrosclerosis (Chang et al., 2007) . Furthermore, circulating follistatin concentrations have been reported to increase concurrently with plasma CRP levels in patients with septicemia (Michel et al., 2003) and in women with PCOS (Chen et al., 2009) , as also shown in this study. Since the time distance part of the sampling may lead to the elevation of follistatin prior to CRP as reported in a previous study for parturition (Rae et al., 2007) , the present study design cannot determine the parallel association between follistatin and CRP. However, the aforementioned data indicate that follistatin can be considered as another useful marker to evaluate inflammatory status. Thus, in the present study, we used follistatin as an additional surrogate marker to evaluate the low-grade inflammatory status in women with PCOS after OC therapy.
In the current study, we found that the difference in hsCRP, HOMA-IR and fasting insulin levels from baseline to after treatment with OCs for 3 months was more pronounced as significant in nonobese women with PCOS. The possible explanation for this may be because the chosen subjects were too obese to highlight the aggravating effect of IR after OC treatment. However, the significant elevation of follistatin concentration after OC therapy in comparison to baseline was found in obese and non-obese women with PCOS. This finding provides further evidence of an aggravated low-grade inflammatory response with OC use. Additionally, the findings of the present study also imply that follistatin might be a more sensitive marker than hsCRP alone to detect a low-grade inflammatory response in both obese and non-obese women with PCOS after OC treatment. However, we still cannot exclude the possibility that the elevated follistatin and hsCRP levels seen after OC treatment in this study might be attributed to increased secretion from hepatocytes in response to oral hormonal therapy rather than to an acute inflammation process. Therefore, further studies to investigate the pathways by which OCs induce elevations of hsCRP and follistatin are still necessary.
A significant difference in baseline follistatin levels was seen in this study among obese and non-obese women with PCOS; however, the association between obesity and follistatin level was not found after OC therapy. Studies have yielded conflicting results regarding the relationship between body weight and follistatin levels (Eldar-Geva et al., 2001; Norman et al., 2001) for women with PCOS, without considering the effect of low-grade inflammation. According to the results of the present study and our previous study (Chen et al., 2009) , the relationship between BMI and follistatin would become not significant after adjustment for the hsCRP level in women with PCOS. Therefore, we suggest that the conflicting results of the association between body weight and follistatin level in women with PCOS might be caused by the confounding effect of chronic inflammation, partially manifested by elevated hsCRP levels.
In conclusion, our study showed that follistatin might be more sensitive than hsCRP alone as a marker of IR and low-grade inflammation in obese women with PCOS after OC treatment. Increased hsCRP and follistatin levels during treatment with OCs in women with PCOS might be an indication of an increased risk of future cardiovascular disease. Since women with PCOS already exhibit an increased incidence of low-grade inflammation, caution should be exercised in prescribing the OCs for women with PCOS. P-values are indicated in parentheses; Diff-: the difference in variables from baseline to after treatment with OCs for 3 months; NS, non-significant at P 0.1; refer to Table I for abbreviations.
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